Shebli Atrash (S Atrash)

ORCID

Publication Activity (10 Years)

Years Active: 2012-2024
Publications (10 Years): 11

Top Venues

Cancers

Life (Basel, Switzerland)

OncoTargets and therapy

Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Carolinas HealthCare System

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Carolinas HealthCare System Jul 03 2017

United States

Physician :: Hematology Oncology

Myeloma Institute for Research and Therapy Aug 01 2011

United States

Publications

Barry A Paul, Faiz Anwer, Shahzad Raza, Aytaj Mammadzadeh, Bayan Khasawneh, Sara Shatnawi, Joseph McGuirk, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Mushtaq, Al-Ola Abdallah, Shebli Atrash
Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma. Cancers 16 (17) (2024)
Hamid Ehsan, Myra M Robinson, Peter M Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A Paul
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life (Basel, Switzerland) 14 (3) (2024)
Hamid Ehsan, Myra M Robinson, Peter M Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A Paul
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life (Basel, Switzerland) 14 (3) (2024)
Shebli Atrash, Aytaj Mammadzadeh, Fulei Peng, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari, Al-Ola Abdallah, Hamza Hashmi
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy. Cancers 15 (11) (2023)
Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, Al-Ola Abdallah
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma. Cancers 15 (19) (2023)
Doris K Hansen, Surbhi Sidana, Lauren C Peres, Christelle M Colin-Leitzinger, Leyla Shune, Alexandria Shrewsbury, Rebecca M Gonzalez, Douglas W Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, Mehmet Hakan Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Aimaz Afrough, Ankit Kansagra, Peter M Voorhees, Rachid C Baz, Jack Khouri, Melissa Alsina, Joseph P McGuirk, Frederick L Locke, Krina K Patel
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Shebli Atrash, Tamara K Moyo
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. OncoTargets and therapy 14 (2021)
Shebli Atrash, Kulsum Bano, Bradley Harrison, Al-Ola Abdallah
CAR-T treatment for hematological malignancies. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 68 (5) (2020)
Manisha Bhutani, David M Foureau, Shebli Atrash, Peter M Voorhees, Saad Z Usmani
Extramedullary multiple myeloma. Leukemia 34 (1) (2019)
Al-Ola A Abdallah, Daisy Alapat, Varinder Kaur, Shebli Atrash
Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (5) (2019)
Shebli Atrash, Myra Robinson, Daniel Slaughter, Amanda Aneralla, Taylor Brown, Jordan Robinson, Ami Ndiaye, Chelsea Sprouse, Qing Zhang, James T Symanowski, Reed Friend, Peter M Voorhees, Saad Z Usmani, Manisha Bhutani
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood cancer journal 8 (11) (2018)
R Khan, S Apewokin, M Grazziutti, S Yaccoby, J Epstein, F van Rhee, A Rosenthal, S Waheed, S Usmani, Shebli Atrash, S Kumar, A Hoering, J Crowley, J D Shaughnessy, B Barlogie
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia 29 (5) (2012)

Shebli Atrash (S Atrash)

Publication Activity (10 Years)

Top Topics

Top Venues